DNA甲基化标志物用于hrHPV阳性女性分流的真实世界证据
该研究在台湾比较了细胞学、HPV16/18分型和PAX1m甲基化标志物三种分流工具在hrHPV阳性女性中的表现。结果显示PAX1m与细胞学准确性相似,且准确性和特异性优于HPV16/18,PAX1m阳性者CIN3+发生率显著更高。
要点
- PAX1m分流准确性>90%、敏感性>78%、特异性>92%,与细胞学相当。
- PAX1m准确性和特异性优于HPV16/18分型(91.6% vs 76.9%;92.5% vs 76.8%)。
- PAX1m阳性者CIN3+发生率显著高于阴性者。
核心结论
- PAX1m作为hrHPV阳性女性分流工具,检测CIN3+的临床表现与细胞学相当,准确性和特异性优于HPV16/18分型。
研究设计与样本
- 纳入4762名≥20岁女性,其中502名(10.5%)为hrHPV阳性,对429名30-64岁hrHPV阳性女性分析三种分流工具表现。
- 入组时无宫颈癌的女性每年通过巴氏涂片随访,以组织学确诊的CIN3+为终点。
主要发现
- PAX1m和细胞学在hrHPV阳性女性中准确性>90%、敏感性>78%、特异性>92%。
- PAX1m准确性91.6%、特异性92.5%,均高于HPV16/18的76.9%和76.8%。
- hrHPV阳性女性CIN3+发生率为10.7例/1000人年,PAX1m阳性者发生率显著高于阴性者。
临床怎么用
- PAX1m可作为hrHPV阳性女性的分子分流工具,用于早期检出CIN和预测疾病进展。
- 在缺乏充分细胞学基础设施的地区(如部分东南亚国家),PAX1m尤其有用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Human papillomavirus (HPV) testing as the primary cervical cancer screening followed by reflex cytology if high-risk HPV is present (hrHPV+) is recently adopted in some countries. However, reflex cytology's sensitivity is variable, and a suitable triage approach for hrHPV+ remains controversial. Here, we compared the performance of three triage tools in hrHPV+ women. METHODS: Three triage tools-cytology, HPV16/18 genotyping, and DNA methylation biomarker PAX1m-were analyzed for their clinical performance in hrHPV+ women. In addition, women without cervical cancer at enrollment were followed for histologically confirmed high-grade cervical intraepithelial neoplasia or worse (CIN3+) annually using Papanicolaou smear. RESULTS: Of 4762 women aged ≥20 years enrolled, 502 (10.5%) were hrHPV+. PAX1m and cytology demonstrated similar accuracy (>90%), sensitivity (>78%), and specificity (>92%) as triage tools in 429 hrHPV+ women aged 30-64 years. PAX1m had better accuracy and specificity (91.6% and 92.5%, respectively) than HPV16/18 (76.9% and 76.8%, respectively). The incidence of CIN3+ among hrHPV+ women was 10.7 cases/1000 person-years. The incidence was significantly greater in PAX1m-positive women than in PAX1m-negative women. CONCLUSIONS: PAX1m has comparable clinical performance to cytology and better accuracy and specificity than HPV16/18 as the triage tool for detecting CIN3+ in hrHPV+ women. The PAX1m assay is thus a promising molecular-based triage tool for early detection of CIN and predicting disease progression in hrHPV+ women. It can be especially useful in countries where adequate cytology-based infrastructure is lacking, such as some Southeast Asian countries, for cervical cancer screening and prevention.
引用
- Chang CL, Ho SC, Su YF, et al. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. Gynecol Oncol. 2021. PMID: 33757653. doi:10.1016/j.ygyno.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。